Bayer raised its 2026 profit outlook after its pharmaceuticals division delivered stronger-than-expected third-quarter sales. The German group also lowered its debt forecast, signalling improving growth momentum and a stronger financial position.
Bayer raised its 2026 profit outlook after its pharmaceuticals division delivered stronger-than-expected third-quarter sales. The German group also lowered its debt forecast, signalling improving growth momentum and a stronger financial position.
<iframe src="https://hindustansphere.com/embed/cluster/a6070820fd69b91b083739cb7c9ff88e480ed0b1" width="100%" height="320" style="border:0;max-width:680px" loading="lazy" title="Bayer raises 2026 profit outlook on strong pharmaceuticals performance"></iframe>
